Treatment, Monitoring, and Outcomes
| Parameter | Brazil | Chile | Hungary | India | Italy | South Korea | Philippines | Thailand | Total |
| Patients (n) | 61 | 47 | 65 | 32 | 49 | 9 | 20 | 44 | 327 |
| R-CHOP* | 60 (98) | 44 (94) | 65 (100) | 20 (63) | 43 (88) | 9 (100) | 10 (50) | 29 (66) | 280 (86) |
| Chemotherapy cycles | |||||||||
| <6 | 6 (10) | 10 (21) | 5 (8) | 3 (9) | 1 (2) | 4 (44) | 0 | 2 (5) | 31 (9) |
| 6 | 19 (31) | 25 (53) | 18 (28) | 29 (91) | 43 (88) | 3 (33) | 11 (55) | 14 (32) | 162 (50) |
| >6 | 36 (59) | 12 (26) | 42 (65) | 0 | 5 (10) | 2 (22) | 9 (45) | 28 (64) | 134 (41) |
| Consolidation radiotherapy | |||||||||
| Total | 26 | 5 | 13 | 14 | 1 | 2 | 1 | 4 | 66 (20) |
| Bulky disease† | 13 | 4 | 11 | 11 | 1 | 0 | 1 | 4 | 45 |
| Nonbulky site | 13 | 1 | 2 | 3 | 0 | 2 | 0 | 0 | 21 |
| No. of patients with significant therapy delays or dose reductions | 0 | 14 (30) | 6 (9) | Data incomplete | 8 (16) | 4 (44) | 2 (10) | data incomplete | 41/259 (16) (68 not known) |
| I-PET timing after cycle | |||||||||
| 2 | 59 | 44 | 55 | 27 | 2 | 7 | 16 | 41 | 251 (77) |
| 3 | 2 | 3 | 10 | 5 | 44 | 2 | 4 | 3 | 73 (22) |
| 4 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 (1) |
| I-PET–positive (n) | 21 (34) | 7 (15) | 21 (32) | 11 (34) | 11 (22) | 4 (44) | 16 (80) | 26 (60) | 117 (36) |
| Outcome by country | |||||||||
| 2-y EFS (95% CI) | 80% (68–88) | 89% (76–95) | 80% (67–88) | 74% (54–86) | 76% (61–86) | 78% (36–94) | 74% (48–88) | 68% (50–81) | 79% (74–83) |
| 2-y OS (95% CI) | 86% (74–93) | 91% (79–97) | 88% (77–94) | 81% (62–91) | 87% (72–94) | 78% (36–94) | 82% (53–94) | 79% (60–90) | 86% (81–89) |
↵* Five patients received chemotherapy other than R-CHOP/CHOP (rituximab-CNOP [cyclophosphamide, mitoxantrone, vincristine, prednisone], n = 4; MACOPB [methotrexate, cytarabine, cyclophosphamide, vincristine, prednisolone, bleomycin], n = 1).
↵† Bulky disease defined as > 5 cm.
Data in parentheses are percentages, except where indicated otherwise.